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Abstract
Background: Equine motor neuron disease (EMND) is a spontaneous neurologic disorder of
adult horses which results from the degeneration of motor neurons in the spinal cord and brain
stem. Clinical manifestations, pathological findings, and epidemiologic attributes resemble those of
human motor neuron disease (MND). As in MND the etiology of the disease is not known. We
evaluated the predisposition role of vitamin E deficiency on the risk of EMND.
Methods: Eleven horses at risk of EMND were identified and enrolled in a field trial at different
times. The horses were maintained on a diet deficient in vitamin E and monitored periodically for
levels of antioxidants – α-tocopherols, vitamins A, C, β-carotene, glutathione peroxidase (GSH-
Px), and erythrocytic superoxide dismutase (SOD1). In addition to the self-control another parallel
control group was included. Survival analysis was used to assess the probability of developing
EMND past a specific period of time.
Results: There was large variability in the levels of vitamins A and C, β-carotene, GSH-Px, and
SOD1. Plasma vitamin E levels dropped significantly over time. Ten horses developed EMND within
44 months of enrollment. The median time to develop EMND was 38.5 months. None of the
controls developed EMND.
Conclusion:  The study elucidated the role of vitamin E deficiency on the risk of EMND.
Reproducing this disease in a natural animal model for the first time will enable us to carry out
studies to test specific hypotheses regarding the mechanism by which the disease occurs.
Background
Spontaneous motor neuron diseases are uncommon in
domestic animals. Where they have been subject to study,
these disorders invariably demonstrate a familial pattern,
occurring in specific breeds of animals such as Brittany
Spaniel dogs [1], Brown Swiss cattle [2] and Yorkshire pigs
[3]. Clinical deficits are evident in the first year of life and
often by a few months of age. The neuropathologic find-
ings are a common theme of neurofilament accumulation
in neurons and proximal axons, progressive motor neu-
ron degeneration and spinal muscular atrophy. Accord-
ingly, in 1990, considerable excitement accompanied the
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identification [4] of equine motor neuron disease
(EMND), a sporadically occurring motor neuron disease
affecting several horse breeds including standardbred,
thoroughbred, Quarter horse and Arab breeds. The disor-
der presents in adult horses with a median age of 10 years.
While EMND has been observed most frequently in the
Quarter Horse breed, we believe that this is due to the
manner in which these horses are housed and fed rather
than by a primary genetic determination.
Equine motor neuron disease is a neurodegenerative dis-
order of the horse characterized by progressive weakness,
fasciculations, muscle wasting, and weight loss [4,5]. Post-
mortem studies on afflicted horses revealed that weakness
and muscle wasting result from degeneration of motor
neurons in the spinal cord and brain stem [4]. The nature
and the distribution of the neurodegenerative changes in
EMND are strikingly similar to those reported in human
progressive muscular atrophy, a form of amyotrophic lat-
eral sclerosis (ALS) or Lou Gehrig's disease [6-8]. As in
ALS, horses afflicted with EMND lose 30% of the somatic
motor neurons in the spinal cord and the brain stem
before they manifest clinical signs [9].
In the United States, EMND has been observed and
reported widely but appears to be more common in the
northeastern states [4,10]. The pattern of the disease is
sporadic and typically in a group of horses on a farm, only
a single animal is affected. The annual incidence of EMND
in the U.S. varied by region and ranged from 0 in several
regions to 2.78 per 100,000 horses in New England [10].
Worldwide, the disease has been recognized and docu-
mented in Canada, South America, Europe, and Asia [11-
13]; exceptionally in one stable in Brazil, a high incidence
has been noted.
Epidemiologic observational studies to date on EMND
have established an association between the age of the
horse and the risk of this disease [10,11,14]. The pattern
of age association is similar to the one reported in the
human MND [15] where older hosts are more susceptible
to the disease.
Significant association was observed between a diet poor
in vitamin E and the risk of EMND [5,14,16]. These field
studies were corroborated with clinical laboratory and
histopathological findings. Horses afflicted with EMND
had significantly lower plasma vitamin E levels than nor-
mal horses either from the general population or stablem-
ates [5,14]. Other evidence of hypovitaminosis E was
found on direct and indirect ophthalmoscopic examina-
tion; affected horses reveal a pigmentary retinopathy
which involves the retinal pigment epithelium. While the
vision of affected horses appears normal, there are
changes in the electroretinogram [13,17]. Furthermore,
electron microscopic studies on the spinal cords of EMND
animals have consistently demonstrated the presence of
large endothelial accumulations of lipopigment granules
[18]. In other species, endothelial accumulations of this
nature have been identified as ceroids associated with
vitamin E deficiency [20].
Despite the observations made, it is difficult to conclude
that the observed association between vitamin E defi-
ciency and the risk of EMND is causal because the samples
in which determinations were made were collected at the
same time the cases were diagnosed. We asked whether
feeding horses a diet deficient in vitamin E would put
them at risk for developing EMND. In other words, we
evaluated the causal relationship between exposure to a
diet that is low in vitamin E and the risk of EMND.
Methods
Study Design
We carried out a self-control (ie, each horse was its own
control and the response to the intervention was com-
pared to the baseline data) field trial to address the above-
stated objectives. In this trial, normal horses potentially at
risk of EMND were recruited, baseline data were collected,
and the animals were followed for a period of time to
acclimate the horses to the experimental environment
before the studies began. The protocol for the undertaken
studies was approved by the Institutional Animal Care
and Use Committee at Cornell (Protocol # 94–23). All
procedures have been in compliance with the institu-
tional guidelines developed and monitored by the Center
for Research and Animal Resources at Cornell.
Recruitment of Horses
The potential pool of horses to be considered for the trial
originated from stables in the northeastern United States.
Candidate horses were clinically examined and judged to
be sound, especially with regards to neurologic function.
Blood samples were drawn from candidate horses for
determinations of levels of muscle enzymes and vitamin
E.
In addition to the self-control design, another external
control group was identified from horses that are kept at
the Equine Research Park for teaching purposes. This
group consisted of five horses which were randomly
selected from a horse herd of 40 animals. This parallel
control group was intended to control for the potential
extraneous effect of the likelihood of EMND.
Inclusion Criteria
Candidate horses with low normal levels of vitamin E
(<2.0 µg/ml (Table 1), normal muscle enzymes, and that
were clinically sound were noted and considered at-risk.
Plasma vitamin E levels were determined at least threeActa Veterinaria Scandinavica 2007, 49:17 http://www.actavetscand.com/content/49/1/17
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consecutive times in the candidate horses over a month
period. Horses that had persistently low-normal vitamin E
values and were judged to be clinically normal were
enrolled in the study. As clinical EMND cases typically
(mode values) have plasma vitamin E levels < 0.5 µg/ml,
the levels in candidate horses were twice higher. Only
horses that met all the inclusion criteria were enrolled in
the study. The rationale for targeting horses with low
plasma vitamin E levels was to identify horses at risk and
shortening the follow up period.
Baseline data
Selected horses were transported to Cornell University's
Equine Research Park, where they underwent complete
physical examinations as well as initial plasma assays of
antioxidants (vitamins A, C, and E, and β-carotene). Each
horse received a clinical score according to a multidimen-
sional scale that has several categories, including weight,
evidence of muscle atrophy, weakness, short strides, trem-
bling, recumbency, feet under body, sweating, head hang-
ing, muscle fasciculation, shifting, tail slack, and collapse.
All horses scored within the normal range. Also, all horses
received a thorough eye exam and were scored accord-
ingly. Biopsies from the dorsomedial sacrocaudalis mus-
cle from five horses were examined to confirm their
clinical status of being free of EMND [13]. The biopsies
revealed no evidence of denervation atrophy.
Laboratory procedures
Determination of β-carotene, α-tocopherol, and retinol levels in 
plasma
Aliquots (1 ml) of plasma were transferred to sterile, poly-
propylene, screw-cap microtubes with neoprene O rings
(Sarstedt, Inc.) containing an antioxidant mixture (100 ml
of an ethanolic mixture of propylgallate and EDTA) and
held at -75°C until testing. The analyses were performed
based on high-performance, liquid-liquid partition chro-
matography (HPLC). The analytes of interest were
detected by spectrophotometery (450 nm for β-carotene
for 1.38 min, 325 nm for retinol for 2.9 min, and molec-
ular fluorescence emission at 330 nm for 7.05 min./α-
tocopherol) using a tandem arrangement of two detectors,
i.e., a variable-wavelength UV-Vis detector and a spec-
trofluorometric detector.
Determinations of Vitamin C concentration
All vitamin C plasma levels determination was performed
at the Animal Health Diagnostic Laboratory (AHLD) at
Cornell University using the HPLC analytical method for
ASA described by Burtis and Ashwood [21]. An aliquot of
20 µml was injected into the HPLC. The HPLC system
consisted of a spectrophotometric detector and a reverse
phase HPLC column. The mobile phase was 1 mmol/L
ammonium formate, 7 mmol/L dodecyltrimethylammo-
nium bromide and 40% methanol (taken to pH 5.2 with
formic acid). Elution was isocratic at a flow rate of 0.9 µL/
min and the eluent was monitored at 265 nm.
Determination of glutathione peroxidase (GSHPx)
The activities and concentrations of GSHPx were deter-
mined using a modification of the method described by
Paglia and Valentine [22]. The activities of GSHPx were
measured as the production of NADP+ by the action of
glutathione reductase (GR) on oxidized glutathione
(GSSG) in the presence of NADPH.
Determination of superoxide dismutase (SOD1) in erythrocytes
The erythrocytic levels of superoxide dismutase (Cu, Zn-
SOD1) were determined using the method described by
Paoletti and Mocali [24]. Briefly, heparinized blood sam-
ples collected from horses were centrifuged to harvest the
erythrocytes which were stored at -80°C until used. For
assay, 500 µl of supernatant was treated with 800 µl of
ethanol/chloroform extraction reagent (500 µl ethanol/
300 µl chloroform). The mixture was vortexed for 30 sec-
onds and then spun at 8500 g, resulting in two layers. The
Table 1: Distribution of breed, weight, age, sex, plasma vitamin E levels of horses enrolled in the study
Horse 
Identification
Breed Weight (Kg) Age (years) Sex Initial vitamin E 
values(µg/ml)
Follow-up 
period (month)
801 Mixed 484 ≥10a Mare 1.3b 42
817 Quarterhorse 432 ≥10 Mare 0.91 35
821 Mixed 381 ≥10 Mare 1.4 33
833 Mixed 398 ≥10 Mare 0.84 5*
980 Quarterhorse 522 13 Gelding 1.1 42
985 Thoroughbred 507 9 Mare 1.81 41
986 Mixed 396 ≥10 Gelding 0.84 18
987 Thoroughbred 444 ≥10 Gelding 1.38 41
988 Mixed 425 ≥10 Mare 1.6 4
990 Mixed 392 16 Mare 1.44 29
991 Thoroughbred 450 10 Gelding 1.51 37
aDental estimate
bMean of four consecutive samplesActa Veterinaria Scandinavica 2007, 49:17 http://www.actavetscand.com/content/49/1/17
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top, aqueous layer was further processed for the assay or
frozen at -80°C until assay. Spectrophotometric assay of
the SOD1 activity was based on the enzyme's ability to
inhibit superoxide-driven NADH oxidation.
Maintenance of horses
At Cornell's Equine Research Park, the selected horses (n
= 11) were maintained in an open stall (12 × 18 m) with
a dirt floor and were given access to a wood-fenced dirt
paddock (around two hectares). The horses had no access
to pasture or green grass. All horses were fed a concentrate
feed that was prepared according to National Research
Council (NRC) guidelines, except vitamin E was not
added. Chemical analysis was performed on this feed to
determine the concentrations of vitamin E. The result
showed that the feed contained < 11.98 mg/kg, which is
an insignificant amount of dietary supplement (normal
horse feed would contain 80 µg/kg vitamin E). Each horse
received 2.5 quarts (about 5 lb, or 2.67 Kg) of this com-
mercial feed a day. These horses also were fed mature-
grass hay demonstrated to contain <10 mg/kg of vitamin
E. The hay was provided ad-lib. All horses were followed
for 44 months, and data on their antioxidant levels were
routinely determined.
The external-control horses were managed similarly
except that they had access to pasture and their concen-
trate feed included vitamin E. The hay was provided ad-lib.
All control horses were judged to be clinically sound and
vitamin E determinations were made in all of them. In
addition vitamin A, C, β-carotenes, GSHPx, and SOD1
were also performed on the control horses.
Data collection protocol
Horses enrolled in the study were examined daily by the
animal attendant for any abnormal clinical sign. The vet-
erinarian was notified immediately if any of the horses
manifested a clinical abnormality. Blood samples were
collected at six-month intervals for determination of the
antioxidant levels. Horses that developed clinical signs
compatible with EMND also had blood samples collected
and antioxidant levels determined. Horses succumbing to
EMND or euthanized on the basis of humane considera-
tions had a necropsy performed and the clinical diagnosis
of EMND was confirmed by histopathological examina-
tion of the central nervous tissues for evidence of degener-
ations, such as glial scarring in the ventral gray column
and Wallerian degeneration of the intramedullary portion
of the somatic efferent neurons [4,13].
Data analysis
The significance of changes in vitamins E, A, C, β-caro-
tene, and GSHPx levels between baseline and end of study
levels on the same horse were evaluated using the pair t-
test. The changes in the activities of the SOD1 between
baseline and end of the study were also evaluated using
the pair t-test. Regression-analysis was used to determine
the significance of change of the levels of the antioxidants
in each horse. Rate of change was measured by the value
of the respective regression coefficient. Comparisons
between treatment and control groups were made using
the t-test. All statistical hypotheses were tested at α = 0.05
(type I error).
Survival analysis technique was used to describe the distri-
bution of EMND experience for the horses enrolled in the
study. The distribution was summarized in terms of the
survivor function, (the probability that a horse enrolled in
the study would not develop EMND beyond a specified
time period) and computed using the Kaplan and Meier
method [24].
Results
Baseline data
Eleven horses met the inclusion criteria and were enrolled
in the study. In the recruitment process, we screened 30
horses for vitamin E plasma levels before deciding on the
eleven enrolled. All eleven horses had normal clinical
scores at enrollment. The distribution of breed, age, sex,
and weight of the enrolled horses is shown in Table 1. The
initial plasma vitamin E levels ranged from 0.84 to 1.81
µg/ml with a median value of 1.4 µg/ml (Figure 1). There
was no significant difference in vitamin E levels among
treatment (self-control) horses. There was no significant
difference in vitamin E levels among (parallel) controls
(median = 2.81; range 1.44 – 3.06 µg/ml).
Initial plasma vitamin A levels ranged from 0.10 to 0.26
µg/ml (median = 0.15 µg/ml (Figure 2). Plasma β-caro-
tene levels were similar among the horses in the two
groups (parallel and self-control) (median = 0.01, range =
0.005, 0.06 µg/ml). The median vitamin C level was 2.27
µg/ml (range 1.7 to 3.2 µg/ml). There was no significant
Initial plasma vitamin E levels Figure 1
Initial plasma vitamin E levels. The mean value of 4 replicates 
is shown for each horse enrolled in the study.
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variation in the blood GSH-Px values among horses
(1.594 ± 0.33 µg/ml). All horses in the treatment group
had similar SOD1 activities (1.91 units ± 0.68).
Initial plasma vitamin A levels for the control horses
ranged from 0.18 to 0.3 µg/ml (median = 0.185 µg/ml).
Plasma β-carotene levels were similar among the control
horses (median = 0.043, range = 0.02, 1.14 µg/ml). The
median vitamin C level for the control horses was 2.33 µg/
ml. There was no significant variation in the blood GSH-
Px values among the control horses (1.454 ± 0.32 µg/ml).
The control horses had similar SOD1 activities (1.96 units
± 0.63).
Follow-up
One horse was lost from the study after being enrolled for
five months; the horse (# 833) died because of septicemia
resulting from bacterial infection in the elbow. His-
topathological examinations of the nervous tissues
showed no evidence of EMND in this horse. This horse
was replaced with another that met the aforementioned
inclusion criteria (# 991) (Table 1).
Plasma vitamin E levels dropped significantly in all horses
enrolled in the deficient (self-control) group as evaluated
by the paired t-test (Figure 3). The median percent change
from baseline to end of enrollment in plasma vitamin E
levels was 82 % (range = 47 – 93 %). Figure 4 shows the
rate of change in vitamin E levels (µg/ml) as estimated
from the regression analysis. The average rate of change
was -0.14 (95 % CI (confidence interval) -0.02, -0.26).
There were no significant changes in levels of vitamin A, C
(data not shown), or β-carotene for all horses in the defi-
cient group (Figure 5). There was a variation in the levels
of GSH-Px in horses enrolled in the study over time, but
the changes were not significant. There were no significant
changes in SOD1 activities in the horses between enroll-
ment and end of the study.
Risk of EMND
Overt clinical signs of EMND were observed in 3 horses.
The first horse that showed clinical signs consistent with
EMND was at 18 months post-enrollment. The affected
horse demonstrated the typical clinical signs of progres-
sive weakness, muscle fasciculations, tremor, and wasting.
This horse was euthanized, and the diagnosis of EMND
was confirmed by histopathologic examination of the spi-
nal cord and brain stem. A second and third horse were
diagnosed with EMND after 29 and 33 months of enroll-
ment, respectively. The pathological changes were found
most consistently and abundantly in the ventral horns of
Rate of change in plasma vitamin E levels Figure 4
Rate of change in plasma vitamin E levels. The significance of 
the coefficient was determined using the t-test. All of the 
coefficients were significantly different from zero except for 
horse number 833.
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Plasma levels of vitamin A and β-carotene Figure 2
Plasma levels of vitamin A and β-carotene. Mean values of 
four replicates are shown for each horse at the time of 
enrollment.
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Changes of plasma vitamin E levels. Mean value of vitamin E 
at initial enrolment and at censoring for each horse in the 
study. The significance of changes in the mean values was 
evaluated using paired t-test. The mean of the changes was 
significantly different from zero.
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the spinal cord and certain motor nuclei of the cranial
nerves. Degeneration was less abundant in the spinal gan-
glia.
One of the horses enrolled in the study experienced severe
colic one night, 35 months post-enrollment, and had to
be euthanized. This horse did not show any clinical sign
suspecting of EMND before the episode of colic; however,
nerve tissues collected showed pathological changes that
were consistent with EMND. A fifth horse showed muscle
fasiculations thirty-seven months in the study and a nerve
biopsy was taken for confirmation. The biopsy was not
conclusive and the horse was euthanatized one month
later. The diagnosis of EMND was confirmed by examin-
ing the CNS.
At the conclusion of the follow up period, none of the
remaining five horses showed overt clinical signs suspect-
ing of EMND, and each had a normal clinical score. Spi-
nal-accessory-nerve biopsies were collected from these
horses 41–42 months post-enrollment and examined his-
topathologically for evidence of EMND [13]. All horses
showed pathological changes that were consistent with
the diagnosis of EMND. Figure 6 shows the survival expe-
rience of all horses enrolled in the study. The median time
to develop EMND was 38.5 months (95 percent confi-
dence interval for the median was 33.5, 42.6 months).
None of the external controls that were maintained at the
Equine Research Park developed EMND. Vitamin A, β-car-
otene, and vitamin C value did not vary significantly
between initial enrollment and right censoring (end of the
study) or the control horses. The median and range values
at the end the study were 0.151 µg/ml (range = 0.175 –
0.30), 0.054 µg/ml (range = 0.028 – 0.08), and 3.28 µg/
ml (range = 2.27 – 4.54).
Discussion
In the years after 1990, the newly identified EMND was
viewed as sharing clinical and neuropathologic features
with human MND [4,11] While on epidemiologic
grounds, the equine disease appeared to be purely spo-
radic, we decided to examine equine SOD1 for polymor-
phisms given the association of mutations in this gene
and familial human MND. No association between SOD1
variants and EMND were found [25]. In contrast, our field
visits to farms with EMND cases suggested a connection
between certain dietary practices and the disorder. We
found cases of EMND commonly where horses had no
access to pasture or other green feed and were fed poor
quality food/hay [5,10,14]. Specifically, we performed
this study to investigate a possible causal relation between
a dietary deficiency of vitamin E and the risk of EMND.
The previous evidence was built through observational
studies and, by virtue of their nature, it is impossible to
establish causal relationship between the deficiency in
this antioxidant and the risk of EMND [26]. Vitamin E
determinations on the EMND-afflicted cases and control
horses in the prior observational studies were made at the
time of disease diagnosis. At such a time in the course of
this motor neuron disease, it is impossible to discern
which took place first, the deficiency in the antioxidant or
the development of the disease. Therefore, it was impor-
tant to carry out this dietary trial to establish the chrono-
logical sequence of events and confirm the suspected
causal relationship between the deficiency and the risk of
the disease.
We adopted a field trial design in which we used the horse
as its own control to assess the impact of the vitamin E
deficiency on the same animals and hence minimize the
potential effect of other intrinsic factors. In addition an
external control group was identified to control for the
Survival rates Figure 6
Survival rates. Plot of the survival experience of horses com-
puted using the Kaplan-Meier method.
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effect of extraneous factors that might predispose horses
to the risk of EMND.
In most mammalian species including the horse, uncom-
plicated vitamin E deficiency is almost exclusively an
axonal degenerative disease in the young or a pigmentary
retinal disorder. The axonopathic effect is characterized by
dystrophic changes in the distal axons of spinal proprio-
ceptive tracts with little or more commonly no involve-
ment of motor neurons [19,27]. Our work and that of
others on equine degenerative myeloencephalopathay
(EDM) [19], a disease of young horses (1 to 3 years), fails
to document similar distal axon changes in adult horses
severely deficient of vitamin E. Furthermore, all the horses
enrolled in this study exceeded the age at which they
would be at greatest risk for EDM (horses typically under
3 years of age). All of the horses enrolled in the study
developed the characteristic retinal degeneration that
associated with prolonged vitamin E deficiency [19].
Vitamin E is essential for the integrity and optimum func-
tion of several systems in the body, including nervous,
immune, reproductive, muscular and circulatory systems
[28]. Several and varied human diseases have been attrib-
uted to deficiency in vitamin E, including ischemic heart
disease, atherosclerosis, diabetes, cataract, Parkinson's
disease, Alzheimer's disease, and other neurologic disor-
ders including ALS [28-30]. Vitamin E is a known antioxi-
dant that helps in the neutralization of free radicals [28].
This antioxidant activity is seen as the underlying factor in
most of vitamin E functions – vitamin E blocks the chain
reaction of lipid peroxidation by scavenging the interme-
diate peroxyl radical that is produced in the reaction [31].
In this trial all the horses had a significant reduction in
vitamin E levels for a relatively long period of time
(approximately 3+ years). The severe and chronic defi-
ciency in vitamin E would put horses at risk of oxidative
stress as a result of reduction in antioxidant capacity. We
investigated the hypothesis of oxidative stress in a differ-
ent study where the production of free radicals was exac-
erbated by feeding vitamin E deficient horses a diet that
was supplemented with prooxidants, copper and iron
[16]. Experimental horses developed EMND at a faster
rate than in this current study. No supplements were
added to the diet in the current study.
There is mounting evidence of a role for oxidative stress in
the risk of human motor neuron disease [32,33]. Studies
on cases of familial ALS (FALS) indicate a pathogenesis
related to dominantly inherited point-mutations in the
gene for Cu, Zn superoxide dismutase (SOD1) on chro-
mosome 21 [34,35]. The nature of the toxic gain of func-
tion caused by the SOD1 mutation in FALS has been
elusive [36,37], yet recent studies [34] find that the
mutated gene in transgenic mice places the CNS under
oxidative stress, which secondarily causes a deficiency of
vitamin E [34]. No significant association between SOD1
and the risk of EMND was observed in the current study.
We have found significantly lower levels of plasma and
nervous-tissue levels of vitamin E in EMND cases in com-
parison to controls (16). All horses enrolled in this trial
also had a significant drop in plasma vitamin E levels.
However, findings on vitamin E levels in the human
motor neuron disease are not conclusive. This discrepancy
could be attributed to several factors including the nutri-
tional uptake of the patients at the time of diagnosis. The
disease has a relatively long time between onset and diag-
nosis in humans. It is estimated that the average duration
between onset and diagnosis of ALS is 12 month [38].
Because the clinical signs are typified by weakness and
muscle loss, it is more likely that the patients would react
to the symptoms by changing their dietary intake – which
is likely to include supplementation of minerals and vita-
mins, including vitamin E. In spite of the discrepancy in
reporting the plasma and CSF levels of vitamin E in SALS
patients, there is a consensus that there is increased lipid
peroxidation in the disease [30,40-42].
There has been a long-term interest in vitamin E because
of its role in the integrity of membranes and its associa-
tion with deficiency syndromes that included encephalo-
malacia and muscle weakness in man and animals
[20,39,43]. Such findings have led to exploring its poten-
tial in the therapy of ALS. Although there was an excite-
ment about its therapeutic effect in 1940s [43,44], the
excitement was tempered by the failure of reproducing the
findings in later studies [46].
The levels of other antioxidants in horses enrolled in this
study – vitamins A and C, β-carotene, and GSH-Px – did
not change significantly. This finding is consistent with
reports on human ALS, where the studies found no signif-
icant differences in the plasma levels of vitamin A, β-caro-
tenes, and glutathione peroxidase [30,47,48]. β-carotene,
a precursor of vitamin A, is known to have an important
antioxidant activity. Although there were no significant
changes in vitamin A levels in the horses enrolled in the
study, three horses developed retinal pigmentation. One
of the horses had undetectable levels of plasma vitamin A.
In this study we found no significant difference between
and within horses in relation to the activities of the SOD1
enzyme. These determinations were made over the course
of the study period at predetermined intervals. The last
determinations were made at the onset of the clinical
signs or at censoring. Genetic studies on this disease failed
to show polymorphism in the SOD1 gene [25]. In
humans, decreased activities of the SOD1 enzyme were
reported in FALS patients [39]. The SOD1 findings in thisActa Veterinaria Scandinavica 2007, 49:17 http://www.actavetscand.com/content/49/1/17
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study are similar to the observation made on the human
SALS.
A retrospective study by McGorum et al., [49] reported
that horses on pasture in Scotland were at risk of EMND.
The inference in their study was that access to pasture is a
good indicator for availability of vitamin E. However, the
authors indicated that many of the affected horses had
low plasma vitamin E levels. Such a finding of low vita-
min E plasma levels in those horses invite several specula-
tive explanations including the quality of the pasture,
bioavailability of vitamin E, and the health of the horse in
terms of absorption capacity. In our study we carried out
a controlled field trial to avoid speculative conclusions.
As a spontaneous, sporadic, and progressive degenerative
disorder of bulbospinal motor neurons, EMND bears
close resemblance to SALS [4]. Unlike other spontaneous
animal models, EMND has many clinical, pathological,
and epidemiological features of SALS. Nevertheless, as a
spontaneous animal model EMND offers the prospect
those epidemiologic studies possibly will identify risk fac-
tors with bearing on the pathogenesis of SALS. Moreover,
and in light of this experimental finding where we are able
to reproduce the disease, EMND offers the opportunity to
test specific hypotheses and perform procedures that are
not possible to do in humans.
Conclusion
We believe that EMND, just as ALS, may have a multifac-
torial etiology and that oxidative stress is a major contrib-
uting/predisposing factor, i.e., sufficient cause, in motor
neuron death but not necessarily the sole etiologic agent/
factor. While the dietary practices which appear to favor
the development of hypovitaminosis E in horses are not
new, EMND was not identified prior to 1990. This would
suggest that more than vitamin E deficiency is in play. By
reproducing the disease, we are an in a position to test spe-
cific hypotheses regarding the etiologic factor(s) while
taking into consideration the role of oxidative stress.
Through these etiologic studies we will be able to under-
stand the pathogeneses of the motor neuron disease and
may be able to provide new therapeutic avenues either by
amelioration of the etiologic agent(s) or enforcement of
the oxidative defense.
We believe that the results of our study represent a break-
through in the advancement of the knowledge on the eti-
ology and pathogenesis of EMND. The success of our
efforts in reproducing this disease in a natural model
offers a unique opportunity with great implications to
human health in general and ALS in particular. The find-
ings in this study will allow us both to focus on testing
specific etiologic hypotheses that will add to the under-
standing of this disease and to evaluate critical interven-
tion(s) that can contribute to the treatment and
prevention of the condition.
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